Karyopharm Therapeutics (NASDAQ:KPTI) focuses on the discovery, development, and commercialization of novel first-in-class drugs for the treatment of cancer and other major diseases. With a keen emphasis on innovative therapeutic approaches, the company aims to tackle unmet medical needs, particularly in the oncology sector. Projects spearheaded by Karyopharm often revolve around the utilization of its proprietary SINE technology, designed to modulate nuclear export signals critical in cancer cell proliferation and survival. Their flagship product, selinexor, has made significant impacts in the treatment landscape for multiple myeloma and diffuse large B-cell lymphoma, marking strides towards achieving their objective of transforming cancer care. Through rigorous research and development, Karyopharm strives to expand its portfolio and impact across various cancer types, underscoring its commitment to advancing healthcare solutions.